Spectroscopic analysis of the interaction between tetra-(<i>p</i>-sulfoazophenyl-4-aminosulfonyl)-substituted aluminum (III) phthalocyanines and serum albumins

Zheng, Liqin; He, Yipeng; Lin, Pingping; Liu, Lina; Yang, Hongqin; Peng, Yiru; Xie, Shusen

doi:10.1142/s1793545816500437

Cited by 9 publications

(4 citation statements)

References 30 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interactions between other photosensitizers and HSA have been computed or experimentally determined in several studies [67][68][69]. In comparison with our results, Guevara et al study showed that three glycosylated photosensitizers bind to HSA close to Sudlow's site I and form strong interactions with TRP214 [67].…”

Section: Discussionsupporting

confidence: 81%

“…Zheng et al predicted the interaction of tetra-(p-sulfoazophenyl-4-aminosulfonyl)-substituted aluminium(III) phthalocyanine photosensitizer with HSA. Their study also showed that the photosensitizer interacts with TRP214 AA residue [68]. Szafraniec's study showed that two derivatives of chlorophyll bind to HAS to Sudlow's sites I and II [69].…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Target Prediction of 5,10,15,20-Tetrakis(4′-Sulfonatophenyl)-Porphyrin Using Molecular Docking

et al. 2022

View full text Add to dashboard Cite

Photodynamic therapy has the potential to be a new and effective cancer treatment. Even if in vitro and in vivo research show promise, the molecular mechanism remains unclear. In this study, molecular docking simulations predict the binding affinity of the 5,10,15,20-tetrakis(4′-sulfonatophenyl)-porphyrin tetraammonium photosensitizer on several potential targets in photodynamic treatment. Our results indicate that this photosensitizer binds to several receptor targets, including B-cell lymphoma 2 (BCL-2) and other related proteins BCL-xL, MCL-1, or A1. The binding affinity of the porphyrin derivative with human serum albumin was determined using UV–vis absorption spectroscopy and predicted using molecular docking. We conclude that the studied porphyrin photosensitizer binds to human serum albumin and may inhibit the cancer cell line through its interactions with HIS and MET AA residues from BCL-2, MCL-1, and β-catenin receptors or through its low estimated free energy of binding when interacting with A1 and BCL-B receptors.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 97%

Target Prediction of 5,10,15,20-Tetrakis(4′-Sulfonatophenyl)-Porphyrin Using Molecular Docking

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Albumins, despite relatively low isoelectric point of approximately 4.7, are well-known to strongly bind the acidic drugs mainly into the positively charged binding sites formed prevalently by basic amino acid residues (Lys, Arg, and His). 28 The binding of anionic Pcs to albumins is also well known in the literature, 24,25,29 but reports on the interaction of cationic Pcs with this protein have also been reported. 25,26 However, in line with our previous observations, 12 no qualitative changes in the absorption and emission spectra or Φ F values were observed upon the addition of BSA into a PBS solution of hydrophilic cationic Pcs 4−6, indicating no detectable interaction with this protein (Figures S6, S7).…”

Section: ■ Resultsmentioning

confidence: 95%

Cationic Versus Anionic Phthalocyanines for Photodynamic Therapy: What a Difference the Charge Makes

et al. 2020

View full text Add to dashboard Cite

The literature reports on cationic and anionic phthalocyanines (Pcs) for photodynamic therapy suggest systematically significant differences in activity. In this work, ten different zinc(II) Pcs with carboxylate functions or quaternary nitrogens (hydrophilic anionic, hydrophilic cationic, amphiphilic anionic, and amphiphilic cationic) were investigated, with the aim of revealing reasons for such differences. In vitro assays on HeLa, MCF-7, and HCT-116 cells confirmed higher photoactivity for cationic Pcs (EC 50 ∼ 3−50 nM) than for anionic Pcs (EC 50 ∼ 0.3−10 μM), the latter being additionally significantly more active in serum-free medium. The environmental pH, binding to serum proteins, interaction with biomembranes, differences in subcellular localization, and relocalization after irradiation were found to be the main factors contributing to the generally lower photoactivity of anionic Pcs than that of the cationic derivatives. This result is not limited only to the presented derivatives and should be considered in the design of novel photosensitizers.

show abstract

“…On this sense, aluminum phthalocyanines exhibit a high affinity binding site constant (K ~ 3–4 × 10 7 L mol −1 ) that includes a strong binding site and other weaker sites 44 . For instance, substituted aluminum (III) phthalocyanines interact with domains I and III in bovine serum albumin as the primary and secondary binding sites, respectively 45 . Taking into consideration these high affinity interactions, the design of phthalocyanine–albumin assemblies as novel nanosystems has been explored 46 .…”

Section: Discussionmentioning

confidence: 99%

Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for Parkinson’s Disease

Monge-Fuentes

Mayer

Lima

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease of the central nervous system. Early treatment for PD is efficient; however, long-term systemic medication commonly leads to deleterious side-effects. Strategies that enable more selective drug delivery to the brain using smaller dosages, while crossing the complex brain-blood barrier (BBB), are highly desirable to ensure treatment efficacy and decrease/avoid unwanted outcomes. Our goal was to design and test the neurotherapeutic potential of a forefront nanoparticle-based technology composed of albumin/PLGA nanosystems loaded with dopamine (ALNP-DA) in 6-OHDA PD mice model. ALNP-DA effectively crossed the BBB, replenishing dopamine at the nigrostriatal pathway, resulting in significant motor symptom improvement when compared to Lesioned and L-DOPA groups. Notably, ALNP-DA (20 mg/animal dose) additionally up-regulated and restored motor coordination, balance, and sensorimotor performance to non-lesioned (Sham) animal level. Overall, ALNPs represent an innovative, non-invasive nano-therapeutical strategy for PD, considering its efficacy to circumvent the BBB and ultimately deliver the drug of interest to the brain.

show abstract

Spectroscopic analysis of the interaction between tetra-(p-sulfoazophenyl-4-aminosulfonyl)-substituted aluminum (III) phthalocyanines and serum albumins

Cited by 9 publications

References 30 publications

Target Prediction of 5,10,15,20-Tetrakis(4′-Sulfonatophenyl)-Porphyrin Using Molecular Docking

Target Prediction of 5,10,15,20-Tetrakis(4′-Sulfonatophenyl)-Porphyrin Using Molecular Docking

Cationic Versus Anionic Phthalocyanines for Photodynamic Therapy: What a Difference the Charge Makes

Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for Parkinson’s Disease

Contact Info

Product

Resources

About